The global CRO named clinical research company of the year yet again, as it prepares for final megadeal.
The Wilmington, North Carolina-based contract research organization was named “Clinical Research Company of the Year” at the 2021 PharmaTimes Clinical Researcher of the Year International competition in London. PPD, which went public at the start of 2020, also won the prestigious award last year – a year which saw CROs take a knock at the onset of the pandemic before notably rebounding as many repositioned their offerings to support COVID-19 trials in the new normal. “This is the second year in a row that PPD has won this award, and we are thrilled that our clinical researchers continue to be recognized by PharmaTimes for their talent, work ethic and commitment to this industry year after year,” said Amber Lee, senior vice president of clinical operations for PPD.
In addition to the award, some of the company’s researchers scooped up gold and silver in both the Clinical Research Team and Start Up-Singles categories, along with silver and bronze awards in the Aspiring Clinical Research Associate category and bronze in the In-House CRA category. PPD is the midst of an acquisition by Thermo Fischer, which announced a $17.4 billion offer for the CRO back in April. The transaction is also one of a few megadeals that have dominated the industry this year. Just this past week, the UK’s Competition and Markets Authority announced it had initiated an investigation into the transaction to determine if this would lessen competition. The company employs more than 30,000 professionals worldwide and has conducted trials in more than 100 countries.